ABIVAX stock

ABVX · Euronext Paris · EUR

Compare ABIVAX
€63.00Change from previous close: −17.21%Absolute change: −€13.10

Close · November 20, 2026

Price history

−41.56% over the period

1 year: from €107.80 (November 20, 2025) to €63.00 (November 20, 2026), −41.56%.

Show chart data

Closing prices adjusted for splits: the last close of each month.

DateClose
November 20, 2026€63.00
October 30, 2026€79.05
September 30, 2026€87.80
August 31, 2026€97.55
July 31, 2026€106.30
June 30, 2026€115.50
May 29, 2026€113.40
April 30, 2026€96.45
March 31, 2026€93.60
February 27, 2026€102.60
January 30, 2026€94.80
December 31, 2025€120.40
November 28, 2025€108.00
November 20, 2025€107.80

At a glance

  • The company

    Clinical-stage biotechnology company developing immune-modulating therapeutics for chronic inflammatory diseases

  • Latest results

    Quarter to June 30, 2026 · EPS -€1.47 (estimate -€0.72)

TickerLandia's take on ABIVAX

Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks

Where the price stands

52-wk low€59.30
52-wk high€139.00

−54.68% from the 52-week high

Analysts · 8 analysts

Average target€131.72+109.08% vs. price

Buy 6 · Hold 2 · Sell 0 · Buy

TickerLandia Fingerprint: ABIVAX

Compared with similar companies: very weak momentum, very low earnings stability, and very high risk.

Financials and price compared with 61 companies in the biotechnology industry, worldwide. Momentum and risk compared with 1,160 European stocks.

1 dimension without enough data. Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 22, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated

Valuation

ABIVAX is pricier than similar companies

ABIVAX's Price/book: 13.7, +165% against the median of a group of 10 similar companies (5.18).

Compared with 11 similar companies

ABIVAX's metrics compared with similar companies
MetricABIVAXPosition in the groupBand
Operating margin-6,270.4%Low
ROE-252.3%Low
Debt/equity0.00Low
Price/book13.7High
Net margin0.0%Low

Grey band: the middle half of the group; tick: the median; dot: ABIVAX. All multiples and dividends

TickerLandia analysisHow it is calculated

The financials

The business in numbers

Revenue

€976K

Latest quarter · Q2 2026

Net income

-€117.43M

Latest quarter · Q2 2026

Quarterly net margin

-12,032.1%

Latest quarter · Q2 2026

Numbers and valuation

Full valuation
Market cap
€5.52B
EPS
-€4.31
Volume
842.42K
Daily trading
€11.3M
Dividend yield
0.00%

How ABIVAX is changing

All results
  • Revenue grew 218.2% a year on average over the last 5 years

  • Operating margin fell from −1,136.6% to −5,384.1%

  • Shares outstanding up 385.1% in 5 years

Returns

ABIVAX returns

€1,000 invested in ABIVAX 5 years ago, on November 22, 2021, would be worth €2,409 today: +140.92% in total, +19.25% per year. This is the price return only: dividends are excluded.

PeriodABIVAXCAC 40€1,000 becomes
1 month−24.32%+1.14%€757
6 months−38.78%−2.34%€612
Year to date−47.67%−2.72%€523
1 year−41.56%−0.67%€584
3 years+510.47%+9.39%€6,105
5 years+140.92%+11.58%€2,409
10 years+726.77%+75.02%€8,268

Over the last 6 months it has done better than 3% of the stocks in the Healthcare sector.

Price only, without dividends. Calculate your investment

The chart in detail

ABIVAX: technical analysis

ABIVAX is in a downtrend: the price is below its 50- and 200-session moving averages, and the 200-session average is falling. The price is 53.3% below its all-time closing high (€135.00, July 3, 2026).

Trend
Downward
RSI (14 sessions)
27
Below 30: a strong fall in a short time
vs 200-session average
−35.32%

Active signals

  • New 52-week low.

  • Close below the low of the previous 55 sessions.

  • RSI below 30: the stock has fallen a lot in a short time.

  • Trading on November 20, 2026 was 7.4 times the 20-session average.

Support and resistance

Price areas where ABIVAX has stopped several times in the last year. They describe the chart; they are not forecasts.

  1. Resistance€91.55+45.32%5 touches, last on April 30, 2026
  2. Resistance€87.80+39.37%2 touches, last on September 30, 2026
  3. Resistance€85.05+35.00%2 touches, last on November 12, 2026
  4. Last price€63.00
  5. No support below: the price is near the lows of the year

Volatility and risk

Over the last year it has moved roughly in line with the CAC 40.

Beta (1 year) vs CAC 40
0.92
Volatility (60 sessions, annualised)
56.7%
Largest fall in the last year
−53.33%

Close of November 20, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it

The company

ABIVAX and its competitors

Obefazimod, the lead candidate in its pipeline, is the centre of ABIVAX's work and is being evaluated in moderately to severely active ulcerative colitis, with a separate study running in Crohn's disease. The Paris-based company, a clinical-stage biotech, develops therapies that draw on the body's own regulatory mechanisms to steady the immune response in people with chronic inflammatory diseases. Its programmes are aimed at patients suffering from chronic inflammatory conditions.

Headquarters
Paris, France
Employees
98
Founded
2013
Chief executive
Marc M. de Garidel
ABIVAX and its competitors
CompanyMarket capOperating marginP/E (trailing 12 months)6 months
ABIVAXABVX$6.06B-6,270.4%—−38.78%
Bachem HoldingBANB$6.84B21.8%38.7−2.87%
ALK-AbellóALK.B$7.79B26.6%38.0−7.14%
CamurusCAMX$4.32B37.4%58.7+37.97%
Financière de TubizeTUB$11.25B0.0%104.1+9.99%
Bavarian NordicBAVA$2.72B18.1%12.7+24.00%

Same industry or related industries, similar size. Compare ABIVAX with its competitors · Full profile